Austin, TX Clinical Trials Report — July 2026

Austin participants should act promptly if they match a study nearing its enrollment deadline: 34 recruiting trials are expected to close within the next 90 days, including 4 that accept healthy volunteers. Austin currently has 653 recruiting trials across 385 research facilities, so patients and volunteers have substantial choice—but closing dates can arrive sooner if enrollment targets are reached.

Closing opportunities for patients and healthy volunteers

The closing-soon pipeline is concentrated in cancer and related conditions, with additional opportunities for people affected by asthma, limb loss, or prosthesis use:

• Cancer (3 trials)
• Metastatic cancer (2 trials)
• HER2-negative breast cancer (2 trials)
• Non-small cell lung cancer (2 trials)
• Prosthesis user (2 trials)
• Breast cancer (2 trials)
• Advanced solid tumor (2 trials)
• Asthma (2 trials)
• Amputation; traumatic, leg, lower (1 trial)
• Amputation (1 trial)

Healthy volunteers have 63 recruiting opportunities across Austin overall, while 4 of the closing-soon studies accept healthy participants. Anyone considering a healthy-volunteer study should contact the site now to confirm age, medication, health-screening, and scheduling requirements.

Major new Phase 2 and Phase 3 studies in Austin

Austin opened 12 new trials in July, down from 20 in May. The new-study mix is led by 8 drug trials, along with 3 biological studies and 2 classified as other; one is behavioral. Industry sponsors account for 10 of the new studies, with the remaining two listed as other-sponsored research.

Several large late-stage studies from established pharmaceutical companies stand out:

• Amgen is sponsoring NCT07684235, a Phase 3 extension study evaluating the long-term efficacy, safety, and tolerability of maridebart cafraglutide in adults with obesity or overweight. The planned enrollment is 3,200 participants.
• Sanofi is sponsoring NCT07734649, a Phase 1/Phase 2 study of an RSV and human metapneumovirus vaccine candidate in adults aged 60 and older. The multicenter study plans to enroll 2,400 participants.
• AbbVie is sponsoring NCT07697456, a Phase 2 study of advanced therapies for adults with moderately to severely active Crohn’s disease or ulcerative colitis. Planned enrollment is 2,000 participants.
• Karuna Therapeutics, a Bristol Myers Squibb company, is sponsoring NCT07686263, a Phase 3 relapse-prevention trial evaluating KarXT in schizophrenia. The study plans to enroll 472 participants.
• Axsome Therapeutics is sponsoring NCT07717879, a Phase 3 study of solriamfetol in children aged 6 to under 12 with ADHD. The trial plans to enroll 468 participants.
• Axsome Therapeutics is also sponsoring NCT07717892, a matching Phase 3 study in adolescents aged 12 to under 18 with ADHD, with planned enrollment of 468 participants.

Other new Austin studies address acute myeloid leukemia, asthma, bladder cancer, depression or anxiety symptoms, juvenile idiopathic arthritis-associated uveitis, intimate partner violence, and human metapneumovirus immunization. ADHD is the most frequent new condition category, with 2 studies.

Where Austin participants can look first

Austin’s most active research locations span pediatric medicine, university research, cardiology, neurology, oncology, and industry-sponsored studies. Dell Children’s Medical Center of Central Texas leads the city with 34 recruiting trials. Several other sites offer concentrated access across different specialties:

• Dell Children’s Medical Center of Central Texas (34 trials)
• Research Site (23 trials)
• University of Texas at Austin (21 trials)
• The University of Texas at Austin (21 trials)
• GSK Investigational Site (13 trials)
• Texas Cardiac Arrhythmia Research Foundation (11 trials)
• FutureSearch Trials of Neurology (11 trials)
• NEXT Austin (11 trials)
• Dell Children’s Medical Center (9 trials)
• Austin Heart (9 trials)
• Texas Oncology - Central/South Texas (8 trials)
• Texas Oncology (8 trials)

Families seeking pediatric research may want to begin with Dell Children’s facilities. Adults with heart-rhythm or cardiovascular interests can check Texas Cardiac Arrhythmia Research Foundation and Austin Heart, while neurology studies are concentrated at FutureSearch Trials of Neurology. GSK Investigational Site provides a prominent industry-sponsored option, and Texas Oncology locations are among the city’s key cancer-research destinations.

Who may be eligible this month

Among the new July trials, 3 include children, 1 is female-only, and none is male-only. 9 include older adults. The Sanofi RSV-plus-human-metapneumovirus vaccine study specifically focuses on adults aged 60 and older, while the two Axsome ADHD studies open opportunities for children and adolescents.

Two of the 12 new trials accept healthy volunteers. Across Austin, the larger pool of 63 recruiting healthy-volunteer studies may offer options for people without a diagnosed condition. Eligibility still depends on each protocol, including age, sex, prior treatments, current medications, and screening results.

Other Texas cities to consider

Participants willing to travel can broaden their search beyond Austin. Houston has 51 recruiting trials, followed by Dallas with 27 and San Antonio with 17. Fort Worth has 7, Richardson has 5, and Edinburg has 3. Fort Sam Houston and El Paso each have 2 recruiting trials.

Austin’s new-trial pace has moved from 22 openings in February and 23 in March to 16 in April, 23 in May, 20 in June, and 12 in July; the trend lists 4 for August. With late-stage studies from Amgen, Sanofi, AbbVie, Karuna, and Axsome entering the local pipeline, Austin participants should monitor site listings and contact research teams early as enrollment activity develops.